Andrea O'Hanlon, PA
Physician Assistant · Cambridge, OHNPI 1275826463
Payments from drug & device makers
Across 171 payments — averaging $13.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$484
- Pfizer$454
- Exact Sciences$217
- AstraZeneca$131
- GSK$94
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$81
- plus $852 from 23 others
What the payments were for
- Food & beverage$2,314100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $484 |
| Pfizer | 47 | $454 |
| Exact Sciences | 10 | $217 |
| AstraZeneca | 9 | $131 |
| GSK | 6 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $81 |
| Amgen(2 entities) | 5 | $75 |
| Neurocrine Biosciences, Inc. | 4 | $73 |
| Boehringer Ingelheim | 5 | $73 |
| Dexcom, Inc. | 4 | $63 |
| Novo Nordisk | 4 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $54 |
| Merck | 3 | $43 |
| Boston Scientific | 1 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $38 |
| Corcept Therapeutics | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $28 |
| Edwards Lifesciences | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Abiomed | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Novartis | 1 | $13 |
| Abbott | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,314 in reported general payments places this provider in the 85th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 143 | $115,202 |
| OzempicSemaglutide | 74 | $69,789 |
| VraylarCariprazine Hcl | 44 | $63,608 |
| EliquisApixaban | 81 | $56,717 |
| RybelsusSemaglutide | 23 | $33,966 |
| XifaxanRifaximin | 11 | $33,801 |
| TrulicityDulaglutide | 30 | $30,240 |
| XareltoRivaroxaban | 26 | $26,082 |
| JanuviaSitagliptin Phosphate | 37 | $24,592 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $18,930 |
| FarxigaDapagliflozin Propanediol | 16 | $14,284 |
| MyrbetriqMirabegron | 14 | $7,879 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 56 | $6,638 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 193 | $5,425 |
| Sucralfate | 46 | $4,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $73 | $115,202143 claims |
| Novo NordiskOzempic, Rybelsus | $57 | $103,75597 claims |
| AbbVieVraylar | $484 | $63,60844 claims |
| PfizerEliquis | $454 | $56,71781 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $56 | $33,80111 claims |
| Lilly USA, LLCTrulicity | $28 | $30,24030 claims |
| Johnson & JohnsonXarelto | $15 | $26,08226 claims |
| MerckJanuvia | $43 | $24,59237 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $94 | $23,17741 claims |
| AstraZenecaFarxiga | $131 | $14,28416 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $7,87914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Cambridge
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Alan OdonnellCincinnati$71K
- Brook GramBeloit$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.